Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy by Piwen Wang et al.
RESEARCH Open Access
Green tea and quercetin sensitize PC-3
xenograft prostate tumors to docetaxel
chemotherapy
Piwen Wang1,2*, Susanne M. Henning2, Clara E. Magyar3, Yahya Elshimali1, David Heber2 and Jaydutt V. Vadgama1,4
Abstract
Background: Chemotherapy with docetaxel (Doc) remains the standard treatment for metastatic and
castration-resistance prostate cancer (CRPC). However, the clinical success of Doc is limited by its chemoresistance
and side effects. This study investigated whether natural products green tea (GT) and quercetin (Q) enhance
the therapeutic efficacy of Doc in CRPC in mouse models.
Methods: Male severe combined immunodeficiency (SCID) mice (n = 10 per group) were inoculated with
androgen-independent prostate cancer PC-3 cells subcutaneously. When tumors were established the intervention
started. Mice were administered with GT + Q, Doc 5 mg/kg (LD), GT + Q + LD Doc, Doc 10 mg/kg (HD) or control.
The concentration of GT polyphenols in brewed tea administered as drinking water was 0.07 % and Q was
supplemented in diet at 0.4 %. Doc was intravenously injected weekly for 4 weeks, GT and Q given throughout
the study.
Results: GT + Q or LD Doc slightly inhibited tumor growth compared to control. However, the combination of
GT and Q with LD Doc significantly enhanced the potency of Doc 2-fold and reduced tumor growth by 62 %
compared to LD Doc in 7-weeks intervention. A decrease of Ki67 and increase of cleaved caspase 7 were observed
in tumors by the mixture, along with lowered blood concentrations of growth factors like VEGF and EGF. The
mixture significantly elevated the levels of tumor suppressor mir15a and mir330 in tumor tissues. An increased
risk of liver toxicity was only observed with HD Doc treatment.
Conclusions: These results provide a promising regimen to enhance the therapeutic effect of Doc in a less toxic
manner.
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Background
Prostate cancer is the most commonly diagnosed male
malignancy and the second-leading cause of cancer death
among men in the United States [1]. Chemotherapy with
docetaxel (Doc) remains the standard treatment for meta-
static and castration-resistance prostate cancer (CRPC)
and a backbone in current drug development [2]. Doc
belongs to the family of taxanes and it is a microtubule
stabilizer inducing mitotic arrest and ultimately cell
apoptosis [3]. However, the development of chemoresis-
tance to Doc is observed in most patients associated with
the overexpression of anti-apoptotic gene Bcl-2 and acti-
vation of nuclear factor-kappa B (NFκB) and PI3K/Akt
pathways, which limits its clinical success [2, 4]. The me-
dian progression-free survival with Doc treatment remains
around 6 months and overall survival is less than 2 years
[2]. In addition, there are severe side effects associated
with Doc treatment including the suppression of bone
marrow function leading to immunodysfunction and
anemia [5]. Clearly, it holds high clinical significance to
enhance the efficacy of Doc at lower doses in a less-toxic
manner and to reduce its side effects.
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Green tea (GT) is produced from the leaves of the plant
Camellia sinensis. The anti-cancer activities of GT have
been demonstrated in several cancers including prostate,
mammary gland, colon, pancreas, liver, esophagus and
liver cancer [6, 7]. The major bioactive components of GT
are GT polyphenols (GTPs), mainly including (-)-epigallo-
catechin (EGC), (-)-epigallocatechin-3-gallate (EGCG),
(-)-epicatechin (EC), and (-)-epicatechin-3-gallate (ECG),
with EGCG as the most abundant and most bioactive
component [6]. Quercetin (Q) is a flavonoid widely found
in vegetables and fruits particularly in onions, apples, and
red wine. We were able to demonstrate in vitro that the
combination of GT and Q with Doc synergistically
enhanced the anti-proliferative effect in androgen-
independent PC-3 and LAPC-4-AI cells [8]. The com-
bined effect was associated with increased apoptosis and
cell cycle arrest in both cell lines [8]. Apoptosis through
the mitochondrial (intrinsic) pathway can be initiated by
chemotherapy or other stimuli such as reduced cytokines/
growth factors. The pro-apoptotic BCL2 family proteins
like Bax, Bak and Bcl-2-associated death promotor (Bad)
are important mediators of these signals. Dephosphory-
lated Bad forms a heterodimer with the anti-apoptotic
BCL2 family members Bcl-2 and Bcl-xL, which allows Bax
and Bak to aggregate and initiate apoptosis [8]. The subse-
quent activation of caspases including caspase 3 and 7
leads to the cleavage of their substrate poly (ADP-ribose)
polymerase 1 (PARP1), which is a hallmark of apoptosis
[9]. Apoptosis through mitochondria can be inhibited by
survival signals, such as growth factors and cytokines,
through activation of anti-apoptotic pathways such as the
NFκB pathway. In cytoplasm, NFκB is bound and inhib-
ited by the inhibitor of NFκB protein (IκB). Once IκB is
phosphorylated, NFκB will be released and translocated to
nucleus where it induces the expression of target genes to
promote cell proliferation and survival [10].
The multiple-targeting activities of GT and Q in anti-
carcinogenesis, particularly by targeting the NFκB and
pro-apoptotic pathways, make them ideal candidates to be
combined with Doc to enhance the therapeutic effect in a
less-toxic manner. In in vitro studies we have observed a
synergistic anti-proliferative effect by combining GT and
Q with Doc [8]. The present study was performed to
confirm the combined effect of the mixture in vivo in a
xenograft mouse model. This study provides evidence that
the combination of GT, Q and Doc enhances the chemo-
therapeutic activity of Doc and encourages future use in
clinical practice in treatment of CRPC with enhanced drug
efficacy and reduced side effects.
Methods
Preparation of GT water, Q diet and Doc solution
GT was prepared by brewing one tea bag (Celestial
Seasonings, Boulder, CO) in 240 mL of boiling water
for 5 min. The GT water contained 0.07 % of the major
GTPs including (mg/L): EGC 204 ± 4, EGCG 388 ± 12, EC
44 ± 2, ECG 64 ± 7, and catechin 7 ± 1. GT was freshly
prepared three times per week on Monday, Wednesday
and Friday and administered as drinking water ad libitum.
Q (Sigma-Aldrich, St Louis, MO) was supplemented in
AIN-93G diet at a concentration of 0.4 % by Dyets Inc.
(Bethlehem, PA). Docetaxel Injection (Besse Medical,
West Chester, OH) was diluted in sodium chloride for tail
vein injection.
Animal study
All procedures carried out in mice were approved by the
Charles R. Drew University of Medicine and Science
Institutional Animal Care and Use Committee. Male
severe combined immunodeficiency (SCID) mice (Charles
River Laboratories) of 5–7 weeks old were acclimated to a
sterilized AIN-93G diet (Dyets Inc.) and water for seven
days. Mice were inoculated subcutaneously with 5x105
androgen-independent PC-3 human prostate cancer cells.
The PC-3 cell line (ATCC® CRL-1435™) was purchased
from American Type Culture Collection (Manassas, VA),
where the cells were authenticated by STR DNA profiling
and tested as mycoplasma free. PC-3 cells were main-
tained in RPMI 1640 medium supplemented with 10 %
(v:v) of fetal bovine serum, 100 IU/mL of penicillin and
100 μg/mL of streptomycin at 37 °C in a 5 % CO2 incuba-
tor, and were tested periodically for mycoplasma contam-
ination. The passage of the PC-3 cell line used for the
inoculation was <10. Four weeks after inoculation when
tumors reached a volume of 50–80 mm3 the intervention
treatment started. Mice were randomly assigned to one of
the five groups (n = 10 per group) including: 1) control, re-
ceiving AIN-93G diet + water + vehicle (sodium chloride);
2) GT +Q, receiving Q diet + GT + vehicle; 3) low dose
(LD) Doc, receiving AIN-93G diet + water + 5 mg/kg Doc;
4) GT +Q + LD Doc, receiving Q diet + GT + 5 mg/kg
Doc ; and 5) high dose (HD) Doc, receiving AIN-93G
diet + water + 10 mg/kg Doc [11]. Doc was administered
once a week for 4 weeks, GT and Q throughout the study.
Tumor size was measured once a week with calipers.
Tumor volume was calculated using the formula: length x
width x height x 0.5236 [12]. Mouse body weight was
measured once a week. Mice in the control and GT +Q
groups were sacrificed when they had received 5-weeks
intervention treatment in observance of the institutional
guideline on tumor size. Other groups were sacrificed
2 weeks later.
Apoptosis signaling antibody array assay
Eight tumor samples were randomly selected from each
group for all the following molecular analyses in tumors.
A slide-based antibody array was used for simultaneous
detection of 19 important signaling molecules involved
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in stress response and apoptosis, using a PathScan Stress
and Apoptosis Signaling Antibody Array kit (Cell Signal-
ing Technology, Danvers, MA) following the manufac-
turer’s instructions. Each of these molecules was detected
in duplicate on the same array arranged as shown in
Fig. 2c, and the identity of each numbered molecule listed
in Fig. 2d. Briefly, total protein was extracted from tumor
tissues using RIPA buffer (Santa Cruz Technology, CA),
and diluted to 0.5 mg/mL in Array Diluent Buffer pro-
vided by the kit. The protein samples were incubated with
the array antibodies overnight. A Detection Antibody
Cocktail was added to the samples, followed by the
addition of HRP-linked Streptavidin and substrate. Protein
was visualized using a ChemiDoc XRS chemiluminescence
detection and imaging system (Bio-Rad Laboratories,
Irvine, CA). The density of the spots were quantitated
using Quantity One software (Bio-Rad Laboratories) and
normalized to the α-tubulin levels. Each sample was done
in duplicate.
Western blot analysis of protein markers of apoptosis and
angiogenesis
Total protein was extracted from tumor tissues using
RIPA lysis buffer (Santa Cruz, CA). The Western blot
procedure was described previously [13]. Briefly, 50 μg
of protein was separated on a 4–12 % Bis-Tris gel
(Invitrogen, Carlsbad, CA), electrotransferred to nitrocel-
lulose membranes and blocked in Tris-buffered saline
with 0.1 % Tween 20 and 5 % nonfat milk for 1 h at room
temperature. Membranes were incubated with primary
antibodies for the detection of Bax (sc-493), Bcl-2
(sc-509), and vascular endothelial growth factor (VEGF,
sc-152), respectively. GAPDH protein was used as
loading control. Images were visualized and quantified
using a ChemiDoc XRS chemiluminescence detection
system (Bio-Rad Laboratories). Each sample was done
in duplicate.
Tissue microarray and immunohistochemical analysis of
proliferation
A section of each tumor was fixed in 10 % phosphate
buffered formalin and paraffin-embedded for tissue
microarray and immunohistochemical detection. The
procedures for tissue array assembling and immunohis-
tochemical detection were described before [14]. Briefly,
a total of 6 cylindrical cores 1.0 mm in diameter were
transferred from each donor block to two new paraffin
array blocks. Four-micron sections were cut from each
array for staining. The slides were prepared for immuno-
histochemistry by deparaffinizing and dehydrating,
followed by an alcohol series and washing in PBS. All
samples were incubated in 3 % H2O2 to eliminate en-
dogenous peroxidase activity, and antigens were retrieved
by boiling the slides in a microwave oven. After blocking
with goat serum the slides were incubated with
monoclonal Ki67 antibody (DAKO North America Inc.,
Carpineteria, CA). The slides were counterstained with
hematoxylin. Slides were digitized on a ScanScope AT
(Aperio Technologies, Inc., Vista, CA) and morphometric
analysis performed with Definiens’ Tissue Studio (Defini-
ens Inc., Parsippany, NJ) to determine the percentage of
Ki67 positive cells in a non-biased method.
Measurement of growth factors in blood
Several growth factors play important roles in tumor cell
proliferation and angiogenesis. The blood levels of growth
factors were measured using a Human Growth Factor
ELISA Strip II kit (Signosis, inc., Santa Clara, CA). Eight
blood samples were randomly selected from each group
for this analysis. The kit allows a simultaneous quan-
tification of 8 growth factors, including VEGF, epider-
mal growth factor (EGF), platelet-derived growth factor
(PDGF)-BB, nerve growth factor (NGF)-β, stem cell factor
(SCF), tumor necrosis factor (TNF)-α, fibroblast growth
factor (FGF)-β, and transforming growth factor (TGF)-β.
Briefly, serum samples were diluted by 1:10 and 100 μl
was added to each well of the 8-wells strip coated with dif-
ferent antibodies. After 1 h incubation the wells were aspi-
rated and washed. A biotin-labeled antibody was added to
the samples followed by streptavidin-HRP conjugate. The
luminescence was measured after adding a HRP substrate
solution. The expression level of these growth factors is
proportional to the luminescent intensity.
qRT-PCR analysis of microRNA expression
Total microRNA (miRNA) was extracted from tumor
tissues using a miRNeasy mini kit (Qiagen), and re-
versely transcribed to cDNA using miScript II RT kit
(Qiagen). Specific primers were provided by miScript
Primer Assays for miR-15a (MS00003178), miR-330
(MS00009450), and miR-19b (MS00031584). The quan-
titative real-time (qRT)-PCR procedure was described
previously [15]. Briefly, a miScript SYBR Green PCR kit
(Qiagen) was used for the reaction. The 25 μL final vol-
ume of reaction contained 12.5 μL of 2x QuantiTect
SYBR Green PCR Master Mix, 2.5 μL of 10x miScript
Universal Primer, 2.5 μL of 10x miScript Primer Assay,
2.5 μL of template cDNA, and RNase-free water. The
reaction mixture was incubated at 95 °C for 15 min,
followed by 40 cycles of 94 °C for 15 s, 55 °C for 30 s,
and 70 °C for 30 s. Mature miRNA expression was
calculated using the 2-ΔΔCt method in normalization to
human RNU6-2 snRNA (MS00033740). Each sample was
done in triplicate.
Blood ALT and AST measurement
Side effect is one of the major issues that limit the dosage
and efficacy of most chemotherapy drugs. The damage on
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liver is frequently found with Doc treatment and is an
indicator of Doc toxicity [16]. The blood levels of liver
enzymes like alanine transaminase (ALT) and aspartate
transaminase (AST) are commonly used as markers of
liver damage. The possibility of treatment as well as
cancer related liver damage was evaluated by both blood
enzyme and liver pathological evaluations in the present
study. Blood samples were collected at mouse sacrificing
and serum separated. Eight blood samples were randomly
selected from each group for this analysis. The blood ALT
and AST levels were determined by measuring their col-
orimetric products pyruvate and glutamate, respectively,
using assay kits (Sigma-Aldrich). 20 ul of serum was used
for each reaction and each sample was done in triplicate.
Liver pathological examination
A section of liver tissue was fixed in 10 % phosphate
buffered formalin and paraffin-embedded. Eight liver
samples were randomly selected from each group for
pathological examination. Slides were cut and stained
with H&E. The pathologist Dr. Elshimali did the liver
pathological examination in a blind manner. The liver
condition was graded based on the degree of inflamma-
tion, piecemeal or bridging necrosis with the following
Fig. 1 GT and Q in combination with Doc enhanced the inhibition of PC-3 xenograft tumor growth in SCID mice. Male SCID mice were
inoculated subcutaneously with 5x105 androgen-independent PC-3 prostate tumor cells. The intervention treatments started 4 weeks later when
tumors were established. Doc was injected through tail vein once a week for 4 weeks. GT and Q were administered throughout the study. Tumor
size was measured using caliper and volume calculated using the formula: length x width x height x 0.5236. Data are presented as mean ± SE for
tumor volume (a) or mean ± SD for tumor weight (b). N = 10 per group. GT, green tea; Q, quercetin; Doc 5, docetaxel at 5 mg/kg iv; Doc 10,
docetaxel at 10 mg/kg iv. Different letters at each time points represent significant difference between treatments (P < 0.05)
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criteria: Grade 0: no/minimal inflammation; Grade 1: por-
tal inflammation or lobular inflammation without necro-
sis; Grade 2: mild periportal inflammation and piecemeal
necrosis or focal hepatocellular necrosis; Grade 3: moder-
ate periportal inflammation and piecemeal necrosis or se-
vere focal cell damage; Grade 4: severe periportal
inflammation and piecemeal necrosis or bridging necrosis.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
or mean ± standard error (SE). Comparison of means
was performed by one-way analysis of variance (ANOVA)
with Tukey’s posttest for paired comparison. Differences
were considered significant if P < 0.05. SPSS (Version 20,
Chicago, IL) was used for all statistical analysis.
Results
Enhanced inhibition of PC-3 xenograft tumor growth
Different profiles of tumor growth were observed between
treatments. Only treatments with the HD Doc and
combination of GT +Q+ LD Doc significantly decreased
tumor growth throughout the intervention (Fig. 1a). LD
Doc treatment initially induced a significant inhibition of
tumor growth but after week 8 tumor growth accelerated
(Fig. 1a). GT +Q treatment did not inhibit tumor growth
significantly compared to control (Fig. 1a). In summary at
Fig. 2 Modulation of apoptosis related signaling proteins using antibody array assay. Eight tumor samples were randomly selected from each
group for this analysis. Total protein was extracted from the tumor tissues. A slide-based antibody array was used for simultaneous detection of
19 signaling molecules (c and d) involved in stress response and apoptosis using a PathScan Stress and Apoptosis Signaling Array kit. Each protein
was arranged in duplicate. The names of the proteins with significant changes in concentration were indicated on the images (a) and their concentrations
quantified (b). Data are presented as mean ± SD. GT, green tea; Q, quercetin; Doc 5, docetaxel at 5 mg/kg iv. Columns with different letters represent
significant difference between treatments (P < 0.05)
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week 9, the tumor growth was inhibited by 26 % (GT +
Q), 52 % (LD Doc), and 85 % (GT +Q+ LD Doc)
compared to control. At week 11, the mixture of all three
chemicals reduced the tumor growth by 62 % compared
to LD Doc alone. The combined effect of the mixture was
comparable to that by a two-fold higher dose of Doc
(HD Doc) (Fig. 1a). A consistent pattern was observed
between tumor weight and tumor volume (Fig. 1b).
Increased tumor cell apoptosis
A protein array analysis was performed to determine the
effect of different treatments on apoptotic signaling path-
ways, including molecules involved in the mitochondrial
(intrinsic) pathway such as Bad, caspases, and PARP, and
NFκB pathway. The treatment with GT +Q was not
significantly effective to modulate these pathways in the
tumor tissues compared to control (Fig. 2a and b). Both
LD Doc alone and its combination with GT and Q signifi-
cantly decreased the phosphorylation of Bad protein com-
pared to control. However, a significant increase of
cleaved PARP (by 30 % compared to control) and cleaved
caspase 7 (by 52 %) and decrease of IκBα (by 32 %) were
only achieved by the combination of all three chemicals
(Fig. 2a and b). Western blot analysis of Bax and Bcl-2
protein expression in tumor tissues found no significant
difference in Bax/Bcl-2 ratio with the treatment of GT +Q
or LD Doc alone compared to control. However, the com-
bination of GT, Q and LD Doc significantly increased
the ratio of Bax/Bcl-2 compared to other treatments
(Fig. 3a and b).
Fig. 3 Increased Bax/Bcl-2 ratio and decreased Ki67 protein expression by GT, Q and Doc in combination. Eight tumor samples were randomly
selected from each group for this analysis. The protein expression of Bax and Bcl-2 in tumor tissues was detected by Western blot. Three representative
protein images from each group were demonstrated (a). The ratios of Bax to Bcl-2 are presented as mean ± SD (b). A section of tumor tissue was
formalin-fixed and paraffin-embedded for tissue microarray and immunohistochemical detection. Slides were cut from the arrays and incubated with
primary antibodies for detection of Ki67 (c). The slides were counterstained with hematoxylin. Nuclei were stained in blue and Ki67 in brown color.
The positive rates of Ki67 nuclear staining are presented as mean ± SD (d). GT, green tea; Q, quercetin; Doc 5, docetaxel at 5 mg/kg iv. Columns with
different letters represent significant difference between treatments (P < 0.05)
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Decreased tumor cell proliferation
Tumor cell proliferation under different treatments was
evaluated by the levels of the proliferation marker nu-
clear Ki67 protein in tumor tissues using tissue micro-
array and immunohistochemical analysis. There was no
significant changes in tumor Ki67 levels in GT +Q or
LD Doc alone groups compared to control. However,
the combination of GT and Q with LD Doc significantly
decreased the Ki67 levels compared to both control and
LD Doc (Fig. 3c and d).
Downregulation of tumor growth factors
The tumor stimulating activities of the eight analyzed
growth factors, including VEGF, EGF, PDGF-BB, NGF-β,
SCF, TNF-α, FGF-β, and TGF-β, have been demon-
strated in many studies [17–19]. Several of them such as
EGF and TGF-β were found to be involved in the che-
moresistance to Doc [20, 21]. The capacity of GT, Q and
Doc in reducing the expression of these growth factors
were analyzed in eight tumor tissues from each group.
There was a slight but nonsignificant decrease in the
blood levels of these growth factors with GT +Q or LD
Doc treatment (Fig. 4a). However, the combination of
GT, Q and LD Doc significantly decreased the levels of
most growth factors including VEGF, EGF, NGF-β, SCF,
TNF-α, FGF-β, and TGF-β, by 40 to 70 % compared to
control, with a nonsignificant reduction of PDGF-BB
level (Fig. 4a). To confirm the correlation between the
Fig. 4 Decreased blood concentrations of tumor growth factors and tumor concentrations of VEGF expression by combining GT and Q with Doc. Blood
samples were collected from each mouse at sacrificing and serum separated. Eight blood samples were randomly selected from each group for this
analysis. The levels of 8 growth factors in blood were simultaneously measured using a Human Growth Factor ELISA Strip II kit. Data are presented as
mean ± SD (a). Eight tumor samples were randomly selected from each group for Western blot analysis of VEGF protein expression. Three representative
protein images from each group were demonstrated (b). The relative concentrations of VEGF in tumor tissues are presented as mean ± SD (c). GT, green
tea; Q, quercetin; Doc 5, docetaxel at 5 mg/kg iv. Columns with different letters represent significant difference between treatments (P< 0.05)
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blood and tissue concentrations of these growth factors,
the expression of VEGF in tumor tissues was analyzed
by Western blot. The pattern of VEGF expression in
tumor tissues was consistent with that in blood under
different treatments (Fig. 4b and c).
Modulation of miRNA expression
Several phytochemicals including EGCG and Q have
demonstrated the ability to modulate the expression of
miRNA, a class of small non-coding RNAs that interact
with target mRNA to negatively regulate the gene ex-
pression at the post-transcriptional level [22–24]. The
importance of miRNAs in carcinogenesis has been dem-
onstrated by many studies. MiRNAs have been found to
be involved in tumor growth, invasion, angiogenesis, and
immune evasion, and they are potential therapeutic
targets [25]. To investigate whether miRNAs are respon-
sive to the combination treatment of GT, Q and Doc, we
selected three candidate miRNAs that have been shown
to be involved in prostate cancer, including two tumor
suppressor miR-15a and miR-330 and an oncomiR miR-
19b. A different profile of miRNA expression was observed
in tumor tissues with GT +Q, Doc or their combination
treatment. Both GT+Q and LD Doc alone demonstrated
a non-significant trend to increase the expression of
miR-15a compared to control, while their combin-
ation significantly elevated the level of miR-15a (Fig. 5).
Similarly, the mixture of all three chemicals significantly
increased miR-330 expression compared to other treat-
ments. A significantly increased expression of the
oncogenic miR-19b was observed with LD Doc alone
compared to control, however, the level of miR-19b
was reduced to the control level when combining LD
Doc with GT and Q (Fig. 5).
Reduced risk of liver damage by the combination treatment
Liver toxicity is one of the common and dose-limiting
side effects with Doc treatment. The evaluation of liver
toxicity in this study was performed by measuring blood
levels of the liver enzymes ALT and AST as well as by a
pathological evaluation of liver tissues. There were no
significant changes in blood ALT level with GT +Q, LD
Doc, or their combination treatment compared to con-
trol, as indicated by the formation of pyruvate (Fig. 6a).
However, a significantly elevated level of blood ALT was
observed with the HD Doc treatment. The blood AST
levels were not significantly different among groups
(data not shown). The liver tissues were pathologically
examined (Fig. 6b) and graded as following: 2.2 ± 0.5
(control), 2.2 ± 0.4 (GT +Q), 2.6 ± 0.8 (LD Doc), 2.7 ± 0.6
(GT +Q + LD Doc), and 3.2 ± 0.9 (HD Doc), with a sig-
nificantly higher grade in HD Doc group compared to
control or GT +Q group.
Discussion
This study demonstrates that a combination of GT and
Q with Doc significantly enhanced the potency of Doc
by 2-fold in inhibition of PC-3 xenograft prostate tumor
growth in SCID mice. The combined effect of the mix-
ture was associated with increased apoptosis, decreased
proliferation, and enhanced modulation of multiple sig-
naling pathways. Tumors may have hundreds of gene
mutations and dysfunctions and alternate signaling path-
ways may compensate for lack of function, thus a therapy
targeting single or few pathways may not be effective and
chemoresistance may develop soon. This is one of the
major causes of the failure of most chemotherapy drugs
including Doc [26]. Effort has been made to test the com-
binations of several other chemotherapy drugs such as
vinorelbine and capecitabine with Doc [27]. However, no
superiority to Doc/prednisone effect has been shown in
phase III trials. In addition, these drug-drug combinations
increase the challenge of adverse effects [27].
Natural compounds like GTPs and Q target multiple
signaling pathways and events in anti-carcinogenesis,
therefore in combination with chemotherapy drugs nat-
ural compounds may be able to provide a systemic con-
trol of the disease with enhanced therapeutic effect at
lower doses of the drug. Previous studies showed that
oral administration of GTPs in drinking water equivalent
to a realistic dose for human consumption (4–6 cups of
tea daily for an average adult human) significantly inhib-
ited the growth of xenograft prostate tumors in mouse
models and progression of prostate tumors in transgenic
mice as demonstrated by our group and other
Fig. 5 Modulation of miRNA expression. Eight tumor samples were
randomly selected from each group for this analysis. Total miRNA
was extracted from tumor tissues, reversely transcribed to cDNA and
quantified using quantitative real-time PCR. Mature miRNA expression
was calculated using the 2-ΔΔCt method in normalization to human
RNU6-2 snRNA. Each sample was done in triplicate. Data are presented
as mean ± SD. GT, green tea; Q, quercetin; Doc 5, docetaxel at 5 mg/kg
iv. Columns with different letters represent significant difference
between treatments (P < 0.05)
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investigators [10, 11]. Evidence from human studies is in-
consistent, however, several recent clinical trials have
demonstrated encouraging results [12, 13]. In a phase II
clinical trial of tea in prostate cancer patients, we found
that the consumption of GT at 6 cups a day for 1 month
significantly decreased serum prostate-specific antigen
(PSA) levels and nuclear NFκB staining in radical prosta-
tectomy tissue as compared to control [14]. However, an
analysis of GTPs in the prostate tissues revealed that
about 50 % of EGCG was methylated into less active me-
tabolites, which limits the anti-cancer activity of GT [15].
We found that the combined use of Q, a natural inhibitor
of both catechol-O-methyltransferase (COMT) and multi-
drug resistance-associated proteins (MRPs), with GT sig-
nificantly increased the bioavailability and cellular uptake
of GTPs and decreased their methylation in vitro and
in vivo, leading to a synergistically enhanced inhib-
ition of xenograft prostate tumor growth in SCID mice
[16–18]. Q itself has exhibited chemopreventive activities
especially in prostate cancer through multiple mechanisms,
including the induction of apoptosis and the inhibition
of proliferation and insulin-like growth factor (IGF)-1
pathway [19–22].
The doses of GT and Q used in this study are physiolo-
gically relevant and safe for human consumption [28, 29].
The GT dose used is equivalent to the consumption of
5–6 cups of GT per day for an adult human, and Q
2 g per day for an adult. The same combination of
GT and Q was able to significantly enhance the inhib-
ition of tumor growth compared to GT or Q alone in
SCID mice implanted with androgen-dependent LAPC-4
prostate cancer cells [14]. However, the administration of
GT +Q without Doc was not significantly effective in
inhibition of PC-3 xenograft tumor growth in the present
study. These results are consistent with our previous in
vitro observations that PC-3 cells were less sensitive to
GT and Q compared to androgen-dependent LNCaP
and LAPC-4 cells [30]. Treatment with LD Doc was
initially effective, while tumors started to grow rapidly
after the last dose of Doc and eventually tumors were
Fig. 6 GT and Q reduced the risk of liver damage in enhancing the therapeutic effect of Doc. The liver condition was evaluated with both
blood level of liver enzymes and liver pathological examination. Eight blood and liver samples were randomly selected from each group for this
analysis. The blood alanine transaminase (ALT) level was determined by measuring its colorimetric product pyruvate using assay kit (a). Data
are presented as mean ± SD. For the liver pathological examination, a section of liver tissue was fixed in 10 % phosphate buffered formalin and
paraffin-embedded. Slides were cut and stained with H&E. The liver condition was graded based on the degree of inflammation, piecemeal or
bridging necrosis, and representative images from each group were presented (b)
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not significantly smaller compared to control. However, a
sustained inhibition of the tumor growth was achieved by
the mixture of GT, Q, and LD Doc with a tumor growth
inhibition comparable to that by a 2-fold higher dose of
Doc treatment but without liver toxicity. Nevertheless, the
treatment with the high dose Doc was associated with an
increased risk of liver damage. These results indicate a
promising clinical success of the mixture of GT, Q and
Doc with enhanced therapeutic effect and reduced risk of
side effects.
The combined effect of the mixture was associated with
increased modulations on multiple signaling pathways and
events. The mixture increased apoptosis of tumor cells as
indicated by an increased ratio of Bax/Bcl-2 and down-
stream activation of caspase 7 along with increased cleav-
age of its substrate PARP1. A similar pattern of GT, Q and
Doc in induction of apoptosis was also observed in our
previous cell culture studies in PC-3 cells [8]. Reduced
phosphorylation of Bad protein may contribute to tumor
cell apoptosis in the present study, which allows the pro-
apoptotic proteins Bax and Bak to aggregate and initiate
apoptosis [31]. The decrease of IκB protein expression or
phosphorylation in the present study suggests a potential
role of the NFκB pathway in mediating the activity of the
mixture. The tumor inhibitory effect through the inhib-
ition of NFκB pathway was also demonstrated in previous
studies [32]. In addition, our data demonstrated that
a decrease in tissue protein content of a variety of
growth factors including VEGF may play an important
role in the reduction of tumor growth by GTP, Q and
Doc [7, 33].
The present results also demonstrate the involvement
of miRNA in the activity of GT, Q and Doc. The down-
regulation of the tumor suppressor miR-15a and miR-
330 has been widely found in prostate tumors compared
to normal tissues particularly in more advanced tumors,
associated with tumor cell survival, proliferation and in-
vasion [34, 35]. The cluster of miR-15a/miR16-1 was re-
ported to target Bcl-2, CCND1 (encoding cyclin D1) and
WNT3A, leading to tumor cell growth arrest and apop-
tosis [34]. The miR-330 has been shown to induce apop-
tosis possibly by targeting E2F1 and inhibit cell motility
in PC-3 cells [35, 36]. In contrast, miR-19b, a potential
oncomiR, was found to be involved in the suppression of
the tumor suppressor phosphatase and tensin homologue
(PTEN) and promote the proliferation of prostate cancer
cells [37]. The increased miR-19b expression under Doc
treatment in the present study may suggest a role of
miR-19b in development of Doc resistance. The abil-
ity of GT and Q in combination with Doc to upregu-
late the expression of miR-15a and miR-330 and to
balance miR-19b expression may partly contribute to
the tumor inhibitory effect of the mixture in the
present study.
Conclusions
In summary, the combination of GT and Q with Doc
significantly enhanced the potency of Doc in inhibition
of PC-3 xenograft prostate tumor growth in SCID mice
by targeting multiple events and signaling pathways
involved in apoptosis and proliferation. This study pro-
vides a novel regimen to enhance the therapeutic effect
of Doc in a less-toxic manner and reduce its risk of side
effects in treatment of CRPC. These results warrant
future clinical trial studies to confirm the combined effect
of this mixture in humans.
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